CD274 and non-small cell lung carcinoma: In the subgroup of NSCLC patients with high PD-L1 expression (PD-L1≥50%), the magnitude of benefit with pembrolizumab compared with chemotherapy increased to 19.7 months vs. 9.7 months (HR=0.67).